|
| Press Releases |
|
 |
|
| Wednesday, May 20, 2015 |
|
|
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer in Japan |
| Eisai Co., Ltd. announced that it has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. more info >> |
|
| Thursday, May 14, 2015 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
more info >> |
|
| Monday, April 27, 2015 |
|
|
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. and Nihon Medi-Physics Co., Ltd. announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. more info >> |
|
| Monday, April 13, 2015 |
|
|
Eisai and Genomics Plc to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development |
| Eisai Co., Ltd. and Genomics plc announced today that they have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. more info >> |
|
| Friday, April 3, 2015 |
|
|
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal |
| A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. more info >> |
|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
| Tuesday, March 3, 2015 |
|
|
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept |
| Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) has been accepted for review by the Jiangsu Food and Drug Administration in China. more info >> |
|
| Monday, March 2, 2015 |
|
|
Eisai Launches Anticancer Agent Lenvima in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. more info >> |
|
| Wednesday, February 25, 2015 |
|
|
Eisai to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has decided to build a new oral solid dose (OSD) production facility at the site of its new Suzhou plant ("New Plant") located within the Suzhou Industrial Park in order to relocate and expand its existing OSD production facility ("Old Plant") within the same industrial park. more info >> |
|
|
Eisai Announces Phase III Trial of Anticancer Agent Halaven in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint |
| Eisai Co., Ltd. announced today that in a Phase III clinical trial (Study 309) of its in-house discovered and developed anticancer agent eribulin mesylate in patients with soft tissue sarcomas, eribulin demonstrated a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, and the study met its primary endpoint. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Typhoon special arrangements for Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks
Jul 19, 2025 21:09 HKT/SGT
|
|
|
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis
Jul 18, 2025 21:00 HKT/SGT
|
|
|
Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit 
Jul 18, 2025 17:00 HKT/SGT
|
|
|
Doubleview Gold Corp Provides Comprehensive Update on Its Flagship Project - the Polymetallic Hat Deposit
Jul 18, 2025 14:09 HKT/SGT
|
|
|
Honda Koraidon First Showrun during Suzuka 8 Hours
Jul 18, 2025 11:06 JST
|
|
|
SJC2 optical submarine cable in operation
Jul 18, 2025 9:36 JST
|
|
|
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability
Jul 18, 2025 00:05 HKT/SGT
|
|
|
Belgian Aircrew Completes MQ-9B Training
Jul 18, 2025 00:05 HKT/SGT
|
|
|
A New Transatlantic Partnership for European CCA
Jul 18, 2025 00:00 HKT/SGT
|
|
|
IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today
Jul 17, 2025 20:32 HKT/SGT
|
|
|
Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore
Jul 17, 2025 18:45 HKT/SGT
|
|
|
MHI-AP Awarded Long-term Service Contract for the Garabogazkarbamid Fertilizer Plant in Turkmenistan
Jul 17, 2025 19:07 JST
|
|
|
Mitsubishi Motors Premieres the All-New Destinator in Indonesia
Jul 17, 2025 17:21 JST
|
|
|
Hitachi, global investment firm Brookfield, and global commodities trading firm Hartree Begin to Explore a Funding Scheme in the Environmentally-friendly Digital Infrastructure Sector
Jul 17, 2025 14:16 JST
|
|
|
"TOKIO Exciting Anime Workshop" Confirmed - Enjoy "Summer Festival at Anime Tokyo Station" This Summer Vacation
Jul 17, 2025 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
